Baird analyst Catherine Ramsay Schulte said she would use any weakness in Exact Science (EXAS) following its Q4 results as a buying opportunity. She noted the company raised its 2020 outlook for for Cologuard but Q1 was slightly below expectations. She remains confident in the 2020 growth outlook given its recent sales force expansion and improving Pfizer productivity. Ramsay Schulte reiterated her Outperform rating on Exact Sciences shares.
Citi analyst Andrew Baum sees "material upside" for shares of AbbVie (ABBV) and Bristol-Myers (BMY) following trial data showing Pfizer's (PFE) Xeljanz increases cancer and cardiovascular risk. AbbVie and Bristol's share price performances have been held back by concerns over downside risk to Rinvoq and deucravacitinib, respectively, given safety concerns on the JAKi class following the Xeljanz data, Baum tells investors in a research note. However, the analyst believes the FDA is unlikely to re-label or restrict AbbVie's Rinvoq and he does not expect any safety signals for Bristol's deucravacitinib from Phase III trials in psoriasis. Baum reiterates Buy ratings on AbbVie and Bristol-Myers and opened "positive catalyst watches."